Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise, filed this Form 6-K for the month of June 2026. The registrant is headquartered in Melbourne, Australia, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate actions rather than financial performance data.
Material Changes
The primary material event reported is the effective share consolidation. Following this action, the company's shares are now trading under the ticker symbol ATHDA.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves primarily to incorporate the share consolidation exhibit by reference into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the new ticker symbol ATHDA on relevant trading exchanges.
- Confirm the specific ratio and effective date of the share consolidation in Exhibit 99.1.
- Review the referenced Registration Statements (S-8 and F-3) for updated share counts and outstanding options.